We have previously demonstrated [Lu, Williams, Deadman, Salmon, Kakkar, Wilkinson, Baruch, Authi and Rahman (1994) Biochem. J. 304, 929-936] the preferential antagonism of the interactions of the integrin aIIbflb on activated platelets with three immobilized glycoprotein ligands (fibrinogen, fibronectin and von Willebrand factor) by a selected panel of snake-venom RGD (Arg-Gly-Asp)-containing proteins including the disintegrins kistrin and elegantin, and the neurotoxin variant dendroaspin. Kistrin and dendroaspin, although structurally unrelated, contain similar amino acids flanking the tripeptide RGD and behaved as identical antagonists preferentially inhibiting platelet adhesion to immobilized fibrinogen as opposed to fibronectin. In contrast, elegantin, which shares extensive sequence similarity with kistrin but has different amino acids around the tripeptide RGD, preferentially inhibited platelet adhesion to immobilized fibronectin as opposed to fibrinogen. To develop further insights into the mechanisms underlying the preferential antagonism shown by the venom proteins in the adhesion studies, we, in the present study, sought to determine the binding properties of kistrin, elegantin and dendroaspin to the zIIjbfl complex by radioligand kinetic and competition studies. In direct binding experiments, both kistrin and dendroaspin were observed to bind to a single class of binding site on ADP-activated platelets with apparent equilibrium dissociation constant (Kdapp) values of 42 + 2 nM and 21+6 nM respectively. In competition studies, dendroaspin blocked the binding of 1251-labelled kistrin to ADP-activated platelets in a simple competitive manner, with an apparent equilibrium inhibition constant (K,app) of 143+14 nM, from which an indirect Kdapp = 22 nM for dendroaspin was determined. This result suggests that kistrin and dendroaspin bind to the same site on the integrin acllbfl3 consistent with their similar inhibitory properties. In contrast, elegantin recognized two classes of binding sites on the aIIb/3 complex with Kdapp values of 10.5 +0.8 nM and 175+10 nM, and, unlike dendroaspin, did not inhibit the binding of '251-labelled kistrin to ADP-activated platelets. However, in reciprocal experiments both kistrin and dendroaspin inhibited the binding of 125I-elegantin to ADPactivated platelets in a non-competitive manner, with Kiapp values of 34 + 3 nM and 21 + 2 nM respectively. Thus elegantin appears to interact with distinct but interacting sites on the aIIb/ complex from the binding site of kistrin and dendroaspin, consistent with its distinctive inhibitory preferences as shown in platelet adhesion studies. Taken in conjunction with the structural similarities and differences between these three RGD-containing venom proteins, these studies provide indirect evidence that the amino acid environment flanking the residues RGD plays a significant role in determining the binding characteristics and thus functional properties of these ligands.
INTRODUCTION
The platelet integrin acIIbfl3 (Gp Ilb/Illa) mediates platelet aggregation, and potentially supplements platelet adhesion to components of the subendothelial matrix at sites of vascular injury. In its active conformer, this approx. 230 kDa heterodimer is a receptor for several glycoprotein components of the plasma and extracellular matrix including fibrinogen [1] , fibronectin [2] , vitronectin [3] , von Willebrand factor [4] and thrombospondin [5] . The adhesive interactions of the aIIb/J3 complex with these physiological ligands operates via a divalent cation-dependent mechanism involving predominantly the ubiquitous adhesive tripeptide RGD (Arg-Gly-Asp) [6, 7] ; however, a structurally related peptide KQAGDV present exclusively at the C-terminus of the y-chain of fibrinogen is also thought to play a major role in the formation of fibrinogen cross-bridges leading to platelet aggregation [8] [9] [10] [11] . Concurrent with the identification of the minimal adhesive peptides present in these glycoprotein ligands and their putative contact sites on the allb3A complex, considerable attention has also been focused in recent years at developing a greater understanding of the binding mechanisms of physiological ligands such as fibrinogen and fibronectin. Results from several studies suggest that binding of these large glycoprotein ligands to their integrin receptors occurs via a sequential, multivalent mechanism involving a rapid, reversible interaction proceeded by the formation of a stable, irreversible complex [12] [13] [14] [15] . Adhesive regions in fibronectin, distinct from the RGD domain, have been identified but appear to interact relatively weakly with the acIIbf3 complex [14] , suggesting that they probably comprise secondary sites of contact which assist in stabilizing the receptor-ligand complex. This model of the binding mechanism of ligands has been reinforced by the recent demonstration that changes in the conformation of fibrinogen occur as a consequence of binding to the aIIb/Ja complex [16] . However, little is known about the biochemistry of ligand specificity and its inclusion into this developing model, that is, does the primary or secondary adhesive interaction confer the specific binding characteristics of a ligand? Furthermore, of the 224 S. Rahman and others several ligand-binding domains identified in both of the subunits of the OIIbf3 complex by approaches involving the cross-linking of RGD and fibrinogen y-chain peptides (reviewed in [17] ), it is not known which, or whether all, of these regions are involved in physiological adhesion events, as synthetic peptides from either the binding domains of the receptor or the adhesive domains of ligands tend to display low affinity and probably poor selectivity of interaction in competition experiments. However, recent studies suggest that many of the putative ligand-binding regions of the allb/83 complex are spatially clustered at the subunit interface (reviewed in [18] ).
A further imput into our understanding of the operational features of the aHIIb3 complex-ligand interaction is emerging from the use of a novel class of RGD proteins present in snake venoms. These proteins, which include the disintegrin family [19] [20] [21] [22] [23] [24] [25] [26] [27] and the neurotoxin variant dendroaspin (also referred to as mambin [28] [29] [30] ), are characterized by their high affinity of interaction (Kd 10-9-l0-7 M) with both resting and activated forms of the aIIb/3 complex and their capacity to inhibit potently a,IIb,f3-dependent adhesive events. This potency has been attributed to the positioning of the residues RGD at the apex of a flexible and solvent-exposed loop which protrudes away from the remainder of the protein structure [31] [32] [33] [34] .
We have previously reported the antagonistic properties of a selected panel of snake-venom RGD proteins, demonstrating the preferential inhibition of the adhesion of ADP-activated platelets to various immobilized glycoprotein ligands [35] . This preferential antagonistic behaviour led us to speculate on the existence of distinct binding sites for these ligands on the aIIbfl3 complex. In addition, based upon a comparative analysis of their primary structure, we postulated that the amino acid environment flanking the tripeptide RGD in the adhesive domains of these venom proteins may underlie their binding characteristics and thus inhibitory properties. In the present study, we provide further evidence in support of this hypothesis by analysing the binding characteristics of members of this panel of venom proteins to the integrin aMlb/3 on platelets through radioligand kinetic and competition studies.
MATERIALS AND METHODS Materials
Lyophilized snake venoms were obtained from either Latoxan (05150 Rosans, France) or Sigma (Poole, Dorset, U.K.). Fibrinogen was obtained from Kabi (Stockholm, Sweden; Grade L) and its purity and integrity were determined by SDS/PAGE. The aIIbfi3-directed monoclonal antibody (mAb) PM6/248 was kindly donated by J. M. Wilkinson (London, U.K. [36] and a polyclonal antibody to the x5f,1 complex purified from human placenta was obtained from Gibco/BRL. Radioisotopic Na'251 (15.3 mCi//ug of iodine) was purchased from Amersham (Amersham, Bucks., U.K.). Enzymobead Reagent was obtained from Bio-Rad Laboratories (Hemel Hempstead, U.K.). All other chemicals and reagents were obtained from Sigma and Milligen (Watford, Herts., U.K.).
Purification of venom proteins Purification of elegantin, kistrin and dendroaspin was performed as previously described [29, 37] . Briefly, the snake-venom proteins were purified from crude venoms by reversed-phase HPLC using a 0.1 % trifluoroacetic acid (TFA)/acetonitrile solvent system. Lyophilized venom was reconstituted in 0.1 % TFA for 10 min on ice and chromatographed on a Vydac C18 analytical column. and rechromatographed to homogeneity. Purified proteins were characterized by either N-terminal sequencing or mass spectrometry.
lodinatlon of llgands lodination of venom proteins was performed using Enzymobead Radioiodination Reagent (Bio-Rad Laboratories) according to the manufacturer's specifications. Briefly, 20,g of disintegrin was incubated with 1 mCi of carrier-free Na'251 (Amersham) in 10 mM sodium phosphate buffer, pH 7.3, containing 0.2 % (w/v) glucose, in a volume of 150 ,ul including an appropriate quantity of Enzymobead suspension for 10-20 min at room temperature. 1251-labelled protein was separated from free iodine by reversedphased chromatography on Sep-Pak cartridges (Waters). Radiolabelled fractions contained greater than 90% trichloroacetic acid-precipitable isotopic activity and specific radioactivities ranging from (2-5) x 106 c.p.m./,ug were routinely obtained. Radiolabelled fibrinogen was kindly donated by Dr. A. Cohen (King's College Hospital). '251-labelled fibrinogen bound to ADPtreated washed platelets in a saturable and cation-dependent manner with an apparent equilibrium dissociation constant (Kdapp) ranging from 300 to 400 nM.
Preparation of washed platelets
Washed platelets were prepared from platelet-rich plasma (PRP) obtained from healthy individuals who had not taken medication for 9 days before bleeding. PRP was obtained from blood containing 0.32% (w/v) trisodium citrate by centrifugation at 200 g for 15 min at room temperature. Platelets were harvested from plasma by centrifugation at 1200 g for O min at room temperature and resuspended in wash buffer (36 mM citric acid, 100 mM NaCl, 5 mM KCI, 0.5 mM CaCl2, 1 mg/ml glucose, 10 mM Pipes, pH 6.5) containing 1 ,uM prostaglandin E1 (PGE1) and 1 unit/ml apyrase (added just before centrifugation). After re-centrifugation and a further washing cycle in the presence of PGE1 and apyrase, platelets were finally resuspended in adhesion buffer (145 mM NaCl, 5 mM KC1, 1 mM MgCl2, 2 mM CaCl2, 10 mM glucose, 3.5 mg/ml BSA, 10 mM Hepes, pH 7.35) and adjusted to concentrations of (3-5) x 108 cells/ml. Washed platelet suspensions were left to sit for approx. 30 min at room temperature to allow the intracellular cyclic AMP concentrations to return to basal levels and then tested for their ability to aggregate in the presence of exogenously added fibrinogen (1.67 mg/ml) using 10 ,uM ADP as an agonist before their use in ligand binding experiments.
Platelet aggregation
Platelet aggregation, performed with washed platelets (3 x 108/ml) in a final reaction volume of 320 ,ul, was measured as an increase in light transmission as described previously [37] .
Platelet aggregation was induced with ADP (final concn. 50 ,uM) and supported by the addition of 1 and ADP were added simultaneously to the platelet suspension and the incubation period was extended to 60 min (1251-labelled kistrin) or 80 min (1251-labelled elegantin) to ensure equilibrium. At equilibrium, the platelet suspension (300 ,1) was then loaded on to a cushion of 25 % (w/v) sucrose solution containing 1 % (w/v) BSA and centrifuged at 12000 g for 10 min to obtain the platelet pellet. The radioactivities in both pellets and supernatants were determined, indicating the levels of bound and free ligand. Non-specific binding levels were determined in the presence of a 100-fold excess of unlabelled ligand or 10 mM EDTA. For 1251_ labelled fibrinogen-binding inhibition experiments a similar assay procedure was used as described above except that higher platelet concentrations of 5 x 108/ml were used. Both 1261-labelled fibrinogen (300 nM) and competitor were added simultaneously and suspensions were incubated for 60 min at room temperature. Under these conditions, approx. 19000 fibrinogen dimers were bound per platelet in the absence of competitors.
Derivation of equilibrium constants
The term apparent equilibrium dissociation constant (Kdapp) has been adopted throughout the paper as the estimation of dissociation constants were made from saturation binding experiments employing high receptor concentrations, and were not determined as a ratio of the rate constants of the dissociation and association of receptor-ligand complexes. From direct binding experiments (in the absence of competitors) with '251-labelled ligands, Kdapp values were calculated as the reciprocal of the slope of the isotherm derived by the method of Scatchard [38] . For kistrin/dendroaspin competition studies, an indirect Kdapp value for dendroaspin was estimated from the K,.pp value (see Figure 2 [40] ; where L* is the free tracer ligand concentration at equilibrium, Lo* is the free ligand concentration at equilibrium in the absence of competitor, Lt* is the total tracer ligand concentration and Kdapp* is the apparent equilibrium dissociation constant of the tracer ligand (kistrin). Analytical procedures SDS/PAGE was performed according to the method of Laemmli [41] . MS was carried out using a Finnigan MAT Atmospheric Pressure Ionization SSQ 710 C spectrometer.
RESULTS
In a previous study [35] we reported that a selected panel of snake-venom RGD proteins comprising the disintegrins kistrin [19] , elegantin [20] and albolabrin [20] , and the neurotoxin variant dendroaspin [28] [29] [30] showed distinctive inhibitory preferences towards the interactions of the XIIaf83 complex with the different immobilized glycoproteins as summarized in Table  1 . To develop further insights into the mechanisms underlying the inhibitory properties of these venom proteins, we sought to determine the binding characteristics of three members of this panel of inhibitors, kistrin, dendroaspin and elegantin, by radioligand kinetic and equilibrium competition studies.
Kistrin and dendroaspin bind to a similar site on the a,,J3 complex The similar inhibitory properties of kistrin and dendroaspin as determined by platelet aggregation in PRP [28, 29, 37] and platelet adhesion studies ( [35] , Table 1 ), led us speculate that these two structurally unrelated venom proteins might share similar binding characteristics to the aIIbf3 complex. Equilibrium binding studies were therefore performed using an unstirred assay system incorporating washed platelets at a concentration of 3 x 108/ml and ADP as an agonist. The platelet density, which corresponds to a total receptor concentration (R,) of approx. 25 nM (assuming 50000 copies of the ac1,,3 complex per platelet [42] ), was chosen to mimic physiological levels, thereby allowing a more accurate comparison of radioligand binding and functional data. Under the conditions of this assay, the platelets did not aggregate as no increase in light transmission was observed when suspensions were incubated in a Payton aggregometer (results not shown).
The binding of 1251-labelled kistrin to ADP-treated platelets was saturable and bivalent cation-dependent, with a Kdapp= 42 + 2 nM (n = 3, Figure la) . Analysis of the data by the method of Scatchard [15] produced a simple monophasic isotherm, indicating that kistrin bound to a single class of binding site on the azXIJ3 complex (f8max. approx. 209000+20000 copies per platelet). Binding of kistrin was reversible as judged by the addition of a 100-fold excess of unlabelled ligand at equilibrium (results not shown). At the high receptor concentrations used in the assay system, depletion of the free kistrin levels was observed. At equilibrium, the bound fraction of the total ligand present in the incubation mixture varied from 0.72, at a kistrin concentration of 10 nM, to 0.33 at apparent saturation (250 nM), manifested as a rightward a shift in the observed EC50 value of 65 nM (Figure la, inset) by a factor approximately equal to complex were determined both directly using 125I-labelled dendroaspin and indirectly by equilibrium competition studies using 151-labelled kistrin as a tracer ligand [43, 46] . The binding of 1251-labelled dendroaspin to ADP-treated platelets was saturable and bivalent cation-dependent ( Figure Ib, inset) . Scatchard analysis of the binding data indicated that dendroaspin also bound to a single class of binding site on the a,IIb,3 complex with a mean Kdapp of 21.3 nM (n = 2), with approx. 29000-37000 sites per platelet. Binding of dendroaspin to the aIIb,/3 complex was reversible as the addition of a 100-fold excess of unlabelled ligand at equilibrium produced a 50% dissociation of 12511 labelled dendroaspin in 15 min. This dissociation rate is of a similar order of magnitude to that observed for kistrin in the present study and previously reported using ADP-activated platelets [19] . Although depletion of free dendroaspin levels was observed at low concentrations (bound fraction = 0.35 at a total ligand concentration of 10 nM), these levels of ligand depletion were significantly less than those observed for kistrin and were not observed at concentrations approaching saturation (bound fraction = 0.064 at a ligand concn. of 250 nM). The equilibrium binding parameters obtained for both kistrin and dendroaspin with ADP-treated platelets fall within the range observed for disintegrins in other laboratories using a similar assay procedure (Table 2) .
In order to assess comprehensively the binding characteristics of both kistrin and dendroaspin, competition studies were performed by analysing the binding of a single concentration of 1251-labelled kistrin in the presence of increasing amounts of dendroaspin (Figure 2a ) and, reciprocally, by varying the concentration of 1251-labelled kistrin in the presence of a single concentration of dendroaspin (Figure 2b ). In the former analysis, dendroaspin inhibited the binding of 1251-labelled kistrin to ADP-treated platelets in a dose-dependent manner, promoting a maximal 80 % inhibition with an IC50 of approx. 156 nM ( Figure  2a) . The incomplete displacement of kistrin by dendroaspin (80 % as opposed to 100 %) is consistent with the notion of an intracellular pool of 125I-labelled kistrin, produced as a consequence of the internalization of aIIbfi3-kistrin complexes which are inaccessible to external competitor. In contrast with dendroaspin, elegantin did not inhibit the binding of '25I-labelled kistrin to ADP-treated platelets even when present at 8-fold higher concentrations. Using the latter assay design, the in- Figure 2 (a). Making the assumption that a single molecule of dendroaspin displaces a single molecule of kistrin, the data presented in Figure 2 (a) were used to determine the free and bound concentrations of dendroaspin and analysed by the method of Scatchard (Figure 2a, inset) complex Platelet adhesion studies indicated elegantin as having distinct inhibitory preferences from those exhibited by kistrin and dendroaspin ( Table 1 ). The binding characteristics of this disintegrin to the aIIbf3 complex were, therefore, determined for comparison. In common with kistrin and dendroaspin, 1251. labelled elegantin bound to ADP-treated washed platelets in a saturable, cation-dependent manner (Figure 3a, inset) . However, analysis of the equilibrium binding data by the method of Scatchard revealed that elegantin recognized two classes of binding site on the platelet surface; a high-affinity site of Kdapp = 10.5 + 0.8 nM with approx. 4000 sites per platelet, and a loweraffinity site of Kdapp = 175 + 10 nM with approx. 25000 sites per platelet. To determine whether both classes of elegantin-binding sites were present on the cxIIbbS3 complex, the efficacy of the aHIIbA-specific mAb PM6.248 [36] at blocking the binding of both low (30 nM) and higher (175 nM) concentrations of 1251-labelled elegantin to ADP-treated platelets was investigated (Figure 3b ). The results of these experiments demonstrated that the monoclonal reagent PM6.248 was an effective inhibitor of 1251-labelled elegantin binding to platelets, promoting a maximal 80% inhibition at both low and high concentrations of 1251-labelled elegantin. By contrast, a polyclonal reagent with specificity for the c5,l integrin complex was comparatively ineffective. Taken together, these results suggest that both classes of elegantin-binding sites identified by the equilibrium binding analysis are present on the aIIbfls complex. Further evidence in support of this notion was obtained from the analysis of the association kinetics of elegantin (Figure 3c ). Bound levels of elegantin at pre-equilibrium were maximally (at 2 min) 3-fold higher than bound levels at equilibrium (40 min). In contrast, the association kinetics of kistrin and dendroaspin followed a simple rectangular hyperbola with equilibrium attained at approx. mechanism is unknown. As this mode of tracer association kinetics has been observed in the presence of competitor ligands [43] , the elegantin preparations were carefully monitored for the presence ofcontaminants. Two independent criteria, SDS/PAGE analysis and reverse-phase HPLC (Figures 4a and 4b) (Figure 2a ). To investigate this behaviour further, competition experiments with 125I-labelled elegantin were performed using a tracer concentration range corresponding to the limits of the lower-affinity site (see Figure  3a) . In these experiments, both kistrin and dendroaspin effectively Bound and free levels of 1251-labelled elegantin were determined as described for Figure 1 . Both dendroaspin and kistrin inhibited 1251-labelled elegantin binding in a non-competitive manner with Kiapp = 21 +2 and 34+3 nM respectively. All points were determined in triplicate (S.E.M. less than 10%).
inhibited the binding of '251-labelled elegantin to ADP-treated platelets (Figures 5a and Sb) . In contrast to the inhibitory mechanisms observed between kistrin and dendroaspin, both of these ligands inhibited the binding of 251I-labelled elegantin in a non-competitive manner, i.e. reducing the availability of elegantin-binding sites (lowering the value of 8Bmax) without altering the affinity status of remaining sites. Notably, the Kiapp values obtained for kistrin and dendroaspin in these experiments (Klapp = 34 + 3 and 21 + 2 nM respectively) are in excellent agreement with the Kdapp values obtained for these ligands in direct '25I-labelled ligand binding experiments (Figures 1 and 2) , indicating that the binding affinities of both kistrin and dendroaspin were unaffected in the presence of elegantin. These findings are consistent with the observation that elegantin did not inhibit the binding of 125I-labelled kistrin (Figure 2a) , indicating a 'one-way' inhibitory mechanism. Furthermore, the observation that both kistrin and dendroaspin inhibit the binding of 251I-labelled elegantin to the aIIbf3 complex via a similar noncompetitive mechanism provides yet further evidence that these The efficacy of snake venom-derived RGD proteins at inhibiting the binding of 1251-labelled fibrinogen to the alIbfl3 complex and abrogating platelet aggregation is well documented [21] [22] [23] [24] [25] [26] [27] .
In the present study, we analysed the inhibition of the interaction of soluble fibrinogen with the aIIbfl3 complex by the venom proteins in both platelet aggregation and 251I-labelled fibrinogen equilibrium competition studies. In contrast with the observations of the platelet adhesion studies using immobilized fibrinogen ( [35] ; Table 1 Table 2 ), suggesting that occupation of both sites by elegantin contributes to blocking the interactions of fibrinogen with its receptor. The results of these experiments, in agreement with the observations of other laboratories [47] , highlight a close correlation between the binding and pharmacological parameters ofthese antagonists.
DISCUSSION
The integrin aIIbfl3 possesses a broad ligand recognition capability, interacting with several glycoproteins via a cation-RGDdependent mechanism [1] [2] [3] [4] [5] [6] [7] . Furthermore, this complex is known to interact with a structurally related linear peptide stretch KQAGDV located exclusively at the C-terminus of the y-chain of fibrinogen [8, 9] . Although synthetic peptides based upon RGD and y-chain amino acid sequences have been cross-linked to distinct regions of the aIIb/ 83complex (reviewed in [48] ), several additional observations, including the similar structural properties of these two peptides, are consistent with the view that they share a common binding site (for review see [18] ). In addition to the obscure relationship between the binding sites of the RGD and y-chain peptides, little is known about the ligand-binding sites of the several additional glycoprotein ligands of the aIIb.83 complex which interact through an RGD-dependent mechanism, i.e. are their binding sites shared or mutually exclusive? The results of the present study, coupled with our previous work [35] , provide strong evidence for the existence of functionally distinct binding sites on the aHIb,f3 complex for high-affinity snake-venom RGD ligands. The evidence for this hypothesis is derived as follows. Several observations indicate that kistrin and dendroaspin interact with an identical class of binding site on the aIIbf83 complex. These are (i) equilibrium competition studies between kistrin and dendroaspin display simple linear competitive kinetics, (ii) the binding characteristics (i.e. Kdapp value and Scatchard isotherm) of dendroaspin can be accurately determined using kistrin as a tracer ligand, (iii) both kistrin and dendroaspin inhibited the binding of 1251-labelled elegantin to the aIIbf83 complex in a non-competitive manner, and (iv) kistrin and dendroaspin preferentially inhibited platelet adhesion to immobilized fibrinogen as opposed to fibronectin ( [35] ; Table 1 ).
In contrast to the data defining the kistrin/dendroaspin-binding site, several functional properties of elegantin indicate that it binds to at least one functionally distinct site. These are as follows: (a) elegantin preferentially inhibited platelet adhesion to the immobilized fibronectin as opposed to fibrinogen ([35] ; Table   1 These data show that the acIIb/.3 complex has at least two, and possibly more, binding sites for these high-affinity RGD ligands, and opens the possibility that physiological ligands may also bind to distinct regions of this receptor. Indeed, the binding of large ligands such as fibrinogen and fibronectin to the integrin acIIbflS may involve multiple contact sites and a complex multistep binding mechanism. Growing support for this model includes the recent report of the identification of an additional aIIbl3-specific contact site in fibronectin, distinct from the RGDS site, located in the 9th type-III repeat between Asp1373-Thr1383 [49, 50] .
At present the biochemical mechanism underlying the noncompetitive inhibition of the binding of 1251-labelled elegantin to the integrin aIIb,83 by kistrin/dendroaspin ( Figure 5 ) remains unclear, although some insights into how it may operate are beginning to emerge. Recent studies have shown that discrete linear regions in both the aIIb (residues 294-314 [51, 52] ) and fl3
(residues 118-131 [53] ) subunits function as both cation-and ligand-binding sites. Furthermore, D'Souza et al. [53] have shown that occupancy of the aIIbfl3 complex by a single mole of either macromolecular or peptide ligand resulted in the displacement of two moles of cation, suggesting that these cation/ ligand-binding regions of the receptor may be conformationally linked. Thus, the non-competitive mechanism of inhibition of elegantin could be explained by such a model in which receptor occupancy by kistrin/dendroaspin results in displacement of cations from both their site and the lower-affinity elegantin site (Figure 3a) , thereby rendering fewer elegantin sites operational (reducing /mmax). According to this model, elegantin-binding sites in which cations were still bound would be expected to function with normal affinity, a characteristic of the inhibitory mechanism shown in Figure 5 .
An important feature of the results of the present study relates Binding of snake-venom ligands to the integrin al.83 231 to the structural similarities and differences between the snakevenom ligands characterized. The finding that the structurally unrelated proteins kistrin and dendroaspin, which have identical amino acid residues flanking the tripeptide RGD (Table 3) , bind to identical sites on the aI11J?3 complex implies an important role for these amino acids in regulating the binding characteristics of this class of ligand. In addition, kistrin and elegantin share a high degree of amino acid sequence similarity and are likely to share significant structural homology, yet these two disintegrins appear to exhibit distinctive binding and functional characteristics. It is noteworthy that kistrin and elegantin have different amino acid residues flanking the sequence RGD (Table 3) , further highlighting an important functional role for these residues. Consistent with this view are the studies of Dennis and co-workers [54] who demonstrated, by alanine replacement mutagenesis, that residues outside of the RGD loop of kistrin do not appear to regulate the function of this protein provided that the native structure is not perturbed. Although alanine replacement of residues flanking the sequence RGD in kistrin had a minor effect on functional performance, only replacement of Arg49 and Asp5' produced a drastic reduction in the activity of this disintegrin. Thus, residues flanking the sequence RGD in disintegrins appear not to be critical for integrin binding as such, but in light of our observations and those of others [55, 56] , we speculate that they act as specificity regulators by providing a specific chemical environment and/or promoting a specific conformation in which the reactive nucleus provided by the tripeptide RGD is presented. Further support for this notion is emerging from the biochemical characterization of integrin-mediated viral infection [57, 58] . For example, Reider et al. [57] have observed that natural variants of the foot and mouth disease virus (FMDV), which bound poorly to cultured BHK cells compared with tissue-culture-adapted viruses, contained amino acid sequence variation of residues adjacent to the sequence RGD in the primary structure of thc capsid protein VPI. Furthermore, these workers noted that the continued passage of naturally isolated viruses in culture engendered the rapid selection of variants with high cell binding activity (infectivity) resulting from variation of the amino acid sequence adjacent to the tripeptide RGD to those sequences prevalent in tissue-culture-adapted viruses. Taken in conjunction with the findings of the present work, these observations indicate that the variation of the amino acids immediately flanking, or in close linear proximity to, the residues RGD is possibly a widespread mechanism by which the specificity of RGD-dependent ligands towards their receptors can be modulated. The functional characterization of recombinant snake-venom proteins with specific modifications to amino acids flanking the residues RGD is currently in progress.
We wish to thank Dr. J. J. Deadman and Mr. Emmanuel Skordalakes for MS and Dr.
Ander Cohen for donating the radiolabelled fibrinogen. This work was funded by the Thrombosis Research Trust.
